NovaUCD

Technology Transfer Opportunity

Markers for Disease Management and Drug Adherence

OPPORTUNITY:
Markers for disease management and drug adherence.

Description of Technology:
Technology has been developed to remotely monitor and diagnose Asthma, Schizophrenia, Vocal Palsy and Multiple Sclerosis using biomarkers.

Diagnostic procedures include the analysis of acoustic signals, such as those recorded from speech using a mobile phone and the analysis of neurological signals using a lightweight, portable, wireless monitor incorporating active dry-electrodes.

Value Proposition:
Provide remote and objective assessment of a subject as the basis of disease detection and management.

Dramatically cuts the "cost of care" by reducing the need for highly qualified expertise and allowing both clinical and home diagnosis/monitoring. Homecare has been shown to decrease hospital and doctors visits and increase the wellness of those using it.

Market:
Behavioral health management, disease detection and management and disease management and drug adherence.

What type of company would benefit most from this technology?

Primary:

- Healthcare Management Organisation (HMOs)
- Healthcare Insurance Companies

Secondary:

- Clinical Trial Organisations
- Health Service Sector
- Asthma Medical Device Industry

Inventor:
Professor Richard Reilly and colleagues, UCD School of Electrical, Electronic and Mechanical Engineering.

Status:
- US patent application "Remote Assessment of a User" US 11/168,312.
- Testing and trials are taking place in Beaumont Hospital (Asthma and Vocal Palsy), St Vincent's Hospital, Fairview (Schizophrenia) and St Vincent's University Hospital, Elm Park (Multiple Sclerosis).

Opportunity Sought:
The promoters are seeking partners for clinical validation and/or licensing.

Contact:
Dr Ciaran O'Beirne, Manager, Technology Transfer, NovaUCD, Belfield Innovation Park, UCD, Belfield, Dublin 4.

t: +353 1 716 3713
e: ciaran.obeirne@ucd.ie
w: www.ucd.ie/nova